Journal of Bone and Mineral Metabolism

, Volume 31, Issue 4, pp 477–480 | Cite as

Primary hyperparathyroidism in a patient with familial hypocalciuric hypercalcaemia due to a novel mutation in the calcium-sensing receptor gene

  • Aoife M. Egan
  • James Ryan
  • Mardiana A. Aziz
  • Tadhg P. O’Dwyer
  • Maria M. Byrne
Case Report


We describe the clinical and genetic findings in pedigree with a novel mutation in the calcium sensing receptor (CaSR) gene and the unusual coexistence of primary hyperparathyroidism (HPT) and familial hypocalciuric hypercalcaemia (FHH) and its clinical management. The occurrence of both FHH and primary HPT in the same patient has been described rarely. Our pedigree has a novel mutation in the CaSR gene. Parathyroidectomy led to a reduction, but not normalization of the calcium levels in the patient identified as having HPT. The coexistence of HPT and FHH was considered in this patient as her calcium and PTH levels were rising with time. Surgical resection of her parathyroid adenoma resulted in reduction of her calcium levels to above normal and significant reduction in her symptoms of fatigue and low mood.


Calcium Hyperparathyroidism Hypocalciuria 



We are indebted to Professor A. Lienhardt and Dr. Corinne Magdelaine from the Laboratoire de Biochemie et Genetique de l’Hopital Universitaire Dupytren de Limoges (France) and Dr. Anneke Seller from the Oxford Genetics Laboratories (England) who carried out the sequencing of the CaSR gene.

Conflict of interest

All authors have no conflicts of interest.


  1. 1.
    Thakker RV (2004) Diseases associated with the extracellular calcium-sensing receptor. Cell Calcium 35:275–282PubMedCrossRefGoogle Scholar
  2. 2.
    Carmliet G, Cromphat SV, Daci E, Maes C, Bouillon R (2003) Disorders of calcium homeostasis. Best Pract Res Clin Endocrinol Metab 17:529–546CrossRefGoogle Scholar
  3. 3.
    Brown EM (1983) Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56:572–581PubMedCrossRefGoogle Scholar
  4. 4.
    D’Souza-Li L, Yang B, Canaff L, Vai M, Hanley DA, Bastepe M, Salisbury SR, Brown EM, Cole DEC, Hendy GN (2002) Identification and functional characterisation of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcaemia and autosomal dominant hypocalcaemia. J Clin Endocrinol Metab 87:1309–1318PubMedCrossRefGoogle Scholar
  5. 5.
    Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG (1993) Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297–1303PubMedCrossRefGoogle Scholar
  6. 6.
    Bouschet T, Martin S, Henley JM (2008) Regulation of calcium-sensing-receptor trafficking and cell-surface expression by GPCRs and RAMPs. Trends Pharmacol Sci 29:633–639PubMedCrossRefGoogle Scholar
  7. 7.
    Eldeiry LS, Ruan DT, Brown EM, Gaglia JL, Garber JR (2012) Primary hyperparathyroidism and FHH: relationships and Clinical implications. Endocr Pract 18:412–417PubMedCrossRefGoogle Scholar
  8. 8.
    Burski K, Torjussen B, Paulsen AQ, Boman H, Bollerslev J (2002) Familial hypocalciuric hypercalcemia: coincidence or causality? J Clin Endocrinol Metab 87:1015–1016PubMedCrossRefGoogle Scholar
  9. 9.
    Brachet C, Boros E, Tenoutasse S, Lissens W, Andry G, Martin P, Bergmann P, Heinrichs C (2009) Association of parathyroid adenoma and familial hypocalciuric hypercalcaemia in a teenager. Eur J Endocrinol 161:207–210PubMedCrossRefGoogle Scholar
  10. 10.
    Thorgeirsson U, Costa J, Marx SJ (1981) The parathyroid glands in familial hypocalciuric hypercalcaemia. Hum Pathol 12:229–237PubMedCrossRefGoogle Scholar
  11. 11.
    Bilezikan JP, Khan AA, Potts JT Jr, on behalf of the Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab 94:335–339CrossRefGoogle Scholar
  12. 12.
    Silverberg SJ, Shane E, Jacobs TP, Siris ES, Gartenberg F, Seldin D, Clemens TL, Bilezikian JP (1990) Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 89:327–334PubMedCrossRefGoogle Scholar
  13. 13.
    Marx SJ, Stock JL, Attie MF, Downs RW Jr, Gardner DG, Brown EM, Speigel AM, Doppman JL, Brennan MF (1980) Familial hypocalciuric hypercalcaemia: recognition among patients referred after unsuccessful parathyroid exploration. Ann Intern Med 92:351–356PubMedCrossRefGoogle Scholar
  14. 14.
    Frank-Raue K, Leidig-Bruckner G, Haag C, Schulze E, Lorenz A, Schmitz-Winnenthal H, Raue R (2011) Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. Clin Endocrinol 75:50–55CrossRefGoogle Scholar
  15. 15.
    Carling T, Szabo E, Bai M, Ridefelt P, Westin G, Gustavsson P, Trivedi S, Hellman P, Brown EM, Dahl N, Rastad J (2000) Familial hypercalcaemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 85:2042–2047PubMedCrossRefGoogle Scholar
  16. 16.
    Yabuta T, Miyauchi A, Inoue H, Yoshida H, Hirokawa M, Amino N (2009) A patient with primary hyperparathyroidism associated with familial hypocalciuric hypercalcaemia induced by a novel germline CaSR mutation. Asian J Surg 32:118–122PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan 2012

Authors and Affiliations

  • Aoife M. Egan
    • 1
  • James Ryan
    • 1
  • Mardiana A. Aziz
    • 2
  • Tadhg P. O’Dwyer
    • 3
  • Maria M. Byrne
    • 1
  1. 1.Department of EndocrinologyMater Misericordiae University HospitalDublinIreland
  2. 2.Department of PathologyMater Misericordiae University HospitalDublinIreland
  3. 3.Department of SurgeryMater Misericordiae University HospitalDublinIreland

Personalised recommendations